H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study
Clinical trial NCT05167643 · UNKNOWN
Trial details
- NCT number
- NCT05167643
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-23
- Primary completion
- 2022-10-23
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.